What alternative treatments can be used for a patient with major depressive disorder and insomnia who cannot take escitalopram (Lexapro), bupropion (Wellbutrin), mirtazapine, citalopram (Celexa), paroxetine, fluoxetine (Prozac), venlafaxine, or sertraline (Zoloft)?

Alternative Antidepressant Options for MDD with Insomnia

For a patient with MDD and insomnia who cannot tolerate multiple SSRIs, SNRIs, bupropion, and mirtazapine, I recommend starting with doxepin (3-6 mg at bedtime) as it specifically treats both depression and sleep maintenance insomnia, or alternatively nefazodone (200-600 mg/day) which has 5-HT2 blocking properties that improve sleep architecture without the sexual side effects common to SSRIs. 1, 2

Pharmacologic Options Still Available

First-Line Alternatives

Tricyclic Antidepressants (TCAs):

• Doxepin is FDA-approved for insomnia at low doses (3-6 mg) and can treat depression at higher doses (150-300 mg/day) 1, 2

  • Specifically effective for sleep maintenance insomnia
  • Has both antidepressant and hypnotic properties
  • Lower anticholinergic activity than amitriptyline at low doses 2

• Nortriptyline (25-150 mg/day) - secondary amine TCA with less sedation than tertiary amines but still effective for depression 2

• Amitriptyline (50-300 mg/day) - highly sedating, though has more anticholinergic side effects than doxepin 2

  • Note: Evidence shows limited efficacy as monotherapy for insomnia at low doses 2

Important caveat: While guidelines list amitriptyline and nortriptyline as options, recent evidence suggests trazodone, amitriptyline, doxepin, and nortriptyline had remission rates consistently below 11% in real-world settings 3. However, doxepin remains FDA-approved and guideline-recommended specifically for insomnia 1.

Atypical Antidepressants

Nefazodone (300-600 mg/day divided BID):

• 5-HT2 receptor antagonist that improves sleep architecture 4
• Alleviates insomnia without disrupting sleep stages
• Critical warning: Black box warning for hepatotoxicity - requires baseline and periodic liver function monitoring
• Less sexual dysfunction than SSRIs 4

Augmentation Strategies (If Partial Response to Previous Agents)

Since the patient has tried multiple antidepressants, augmentation may be more effective than switching:

Atypical Antipsychotics for Augmentation:

• Quetiapine (25-300 mg at bedtime) - effective for both depression augmentation and insomnia 2, 5

  • Start 25-50 mg for insomnia, can increase for antidepressant effect
  • Monitor for metabolic side effects (weight gain, glucose, lipids)

• Aripiprazole (2-15 mg daily) - FDA-approved for MDD augmentation 5

  • Less sedating, better for daytime function
  • Lower metabolic risk than quetiapine

• Olanzapine (2.5-20 mg) - highly effective but significant metabolic concerns 2, 5

Other Augmentation Options:

• Lithium (300-900 mg/day, target level 0.6-1.0 mEq/L) - well-established augmentation strategy 5

  • Requires regular monitoring (renal, thyroid, lithium levels)

• Lamotrigine (up to 200 mg/day) - effective augmentation, especially if bipolar features 5

• Liothyronine (T3) (25-50 mcg/day) - augmentation strategy even in euthyroid patients 5

Non-Pharmacologic Treatment (Critical Component)

Cognitive Behavioral Therapy for Insomnia (CBT-I) should be initiated immediately as it is the most effective long-term treatment for chronic insomnia and has moderate-certainty evidence for treating depression 6. The 2016 ACP guideline specifically recommends CBT-I as first-line for chronic insomnia disorder 6.

CBT-I Components include: 2

• Stimulus control therapy
• Sleep restriction therapy
• Cognitive therapy
• Relaxation training

This is not optional - CBT-I has superior long-term outcomes compared to pharmacotherapy alone and facilitates medication tapering 2, 6.

Hypnotic Medications for Insomnia Management

While addressing depression, consider short-term hypnotics (should not be sole treatment):

Benzodiazepine Receptor Agonists:

• Eszopiclone (2-3 mg) - for sleep onset and maintenance, no short-term restriction 2
• Zolpidem (10 mg, 5 mg in elderly) - primarily sleep onset 2
• Temazepam (15-30 mg) - short to intermediate acting 1, 2

Melatonin Receptor Agonist:

• Ramelteon (8 mg) - for sleep onset, non-scheduled, no abuse potential 1, 2

Critical warnings for hypnotics: 2

• FDA warnings about sleep-related behaviors (sleepwalking, sleep-driving)
• Should be supplemented with behavioral therapy
• Not recommended as monotherapy for depression with insomnia
• Intended for short-term use only

Medications to AVOID

Do NOT use the following based on guideline recommendations: 1

• Trazodone - despite common off-label use, guidelines suggest NOT using it (weak recommendation) due to insufficient efficacy data
• Tiagabine - not recommended, risk of seizures
• Diphenhydramine - not recommended for chronic insomnia
• Melatonin - insufficient evidence for chronic insomnia
• Valerian - insufficient evidence

Recommended Treatment Algorithm

1. Immediate: Start CBT-I (can be delivered via telehealth or apps if in-person unavailable) 6

2. Pharmacologic choice depends on primary concern:

   • If insomnia is predominant: Doxepin 3-6 mg at bedtime, can titrate up for antidepressant effect 1, 2
   • If depression is predominant with insomnia: Nefazodone 200 mg BID, titrate to 300-600 mg/day (monitor LFTs) 4
   • If previous partial response to any tried medication: Augment with quetiapine 25-50 mg at bedtime or aripiprazole 2-5 mg daily 5

3. Short-term hypnotic bridge (2-4 weeks max): Consider ramelteon 8 mg or eszopiclone 2-3 mg while antidepressant takes effect 1, 2

4. Reassess in 1-2 weeks for suicidality, side effects, and symptom response 7

5. If inadequate response at 6-8 weeks: Switch to alternative or add augmentation strategy 7

Critical Monitoring Points

• Baseline: ECG if using TCAs (QTc prolongation risk), LFTs if using nefazodone
• Week 1-2: Suicidality assessment, emerging side effects 7
• Week 4-6: Sleep and mood symptom response
• Week 8: Decision point for switching or augmentation if inadequate response 7
• Ongoing: Weight, metabolic parameters if using atypical antipsychotics

Common Pitfalls to Avoid

• Do not use low-dose sedating antidepressants alone (like trazodone 50 mg) - they do not constitute adequate MDD treatment 2
• Do not continue ineffective hypnotics long-term - taper and rely on CBT-I 2
• Do not ignore CBT-I - it has the best evidence and prevents relapse 6
• Do not use multiple hypnotics simultaneously without clear rationale
• Do not forget to screen for bipolar disorder before starting antidepressants - TCAs and nefazodone can trigger mania 7